USE OF A CHIMERIC PROTEIN COMPRISING Met-GnRH IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING ADENOCARCINOMA OR HEPATOCARCINOMA 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(IL-118570) שימוש בחלבון כימרי הכולל Met–GnRH בהכנת תכשיר רוקחי לטיפול באדנוקרצינומה או בהפאטוקרצינומה
公开号/公开日
IL118570 A 1996-10-16 [IL-118570]IL118570 B 2007-06-17 [IL-118570] / 1996-10-162007-06-17
申请号/申请日
1996IL-0118570 / 1996-06-04
发明人
YARKONI SHAI;LORBERBOUM-GALSKI HAYA;NECHUSHTAN AMOS;MARIANOVSKY IRINA;
申请人
YISSUM RESEARCH DEVELOPMENT;
主分类号
IPC分类号
A01N-037/18A61K-031/00A61K-038/00A61K-038/22A61K-038/24A61K-039/395A61K-039/40A61K-039/42A61K-039/44A61K-047/48A61P-035/00C07H-021/02C07H-021/04C07KC07K-001/00C07K-002/00C07K-004/00C07K-005/00C07K-007/00C07K-014/00C07K-014/21C07K-014/
摘要
(IL-118570) The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist of Pseudomonas Exotoxin A.  The present invention further relates to pharmaceutical compositions containing as an active ingredient these neoplastic cells targeted chimeric toxins and to a method for the production of these chimeric toxins.  The said invention also relates to a method for cancer therapy, treating malignant carcinoma cells and benign hyperplasia including uterine lyomyoma cells, extra uterian endometrial island cells, benign hyperplasia of prostate and breast and pituitary tumor adenoma cells, by the use of the above-mentioned chimeric toxins.  (From US6933271 B2)
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
1996IL-0118570 1996-06-04
主权利要求
(IL-118570) 1. Use of an effective amount, sufficient to at least reduce the growth of adenocarcinoma or hepatocarcinoma, of at least one fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of methionine gonadotropin releasing hormone (Met-GnRH) or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety, in the preparation of a pharmaceutical composition for use in a method for the treatment of said adenocarcinoma or hepatocarcinoma in a mammal in need of such therapy. 2. A use according to claim 1, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 3. A use according to claim 1, wherein said fused chimeric protein produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 4. A use in according to claim 1, wherein said pharmaceutical composition for systemic administration of said chimeric protein. 5. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in a method of treating a mammal having at least one adenocarcinoma or hepatocarcinoma, comprising administering to said mammal in need thereof, an amount sufficient to ameliorate the effects of said adenocarcinoma or hepatocarcinoma. 6. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having endometriosis. 7. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having a uterine myoma. 8. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having a pituitary adenoma. 9. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met - GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having benign prostatic hyperplasia (BPH). 10. A use of a fused chimeric protein comprising a linear genetically engineered molecule consisting essentially of peptide bonds, produced by fusing, at the level of cDNA: A. DNA encoding at least one cell targeting moiety consisting essentially of Met- GnRH or a Met-GnRH analog that specifically binds to GnRH binding sites on Caco2 adenocarcinoma cells; and B. DNA encoding at least one cell killing moiety in the preparation of a pharmaceutical composition for use in treating a mammal having polycystic breast disease. 11. A use according to claim 5, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 12. A use according to claim 5, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 13. A use according to claim 6, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 14. A use according to claim 6, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 15. A use according to claim 7, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 16. A use according to claim 7, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 17. A use according to claim 8, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 18. A use according to claim 8, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 19. A use according to claim 9, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 20. A use according to claim 9, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE40. 21. A use according to claim 10, wherein said fused chimeric protein is produced by fusing at the CDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GnRH analog, preceded by a Met, to a mutated DNA fragment of the full length Pseudomonas exotoxin (PE), encoding the protein Met-GnRH-PE66. 22. A use according to claim 10, wherein said fused chimeric protein is produced by fusing at the cDNA level an oligonucleotide encoding gonadotropin releasing hormone (GnRH) or a GNRH analog, preceded by a Met, to a DNA fragment comprising domains II and III of the Pseudomonas exotoxins (PE), encoding the protein Met-GnRH-PE40. 23. For the Applicants, RE HOLD COH ND PARTNERS By
法律状态
(IL-118570) LEGAL DETAILS FOR IL118570  Actual or expected expiration date=2011-01-31    Legal state=DEAD    Status=LAPSED     Event publication date=1996-06-04  Event code=IL/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=IL IL11857096  Application date=1996-06-04  Standardized application number=1996IL-0118570     Event publication date=1996-10-16  Event code=IL/A  Event type=Examination events  Application of patent for invention  Publication country=IL  Publication number=IL118570  Publication stage Code=A  Publication date=1996-10-16  Standardized publication number=IL-118570     Event publication date=2007-06-17  Event code=IL/B  Event indicator=Pos  Event type=Event indicating In Force  Granted patent  Publication country=IL  Publication number=IL118570  Publication stage Code=B  Publication date=2007-06-17  Standardized publication number=IL-118570     Event publication date=2008-01-06  Event code=IL/FF  Event indicator=Pos  Event type=Event indicating In Force  Patent granted    Event publication date=2008-01-06  Event code=IL/KB  Event indicator=Pos  Event type=Event indicating In Force  Event type=Restitution or restoration  Patents renewed    Event publication date=2011-01-31  Event code=IL/MM9K  Event indicator=Neg  Event type=Event indicating Not In Force  Patent not in force due to non-payment of renewal fees
专利类型码
AB
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部